NDC 70518-2780-1 - Naloxone Hydrochloride

This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.

Product NDC
70518-2780
Requested NDC
70518-2780-1
Package NDCs from labels
70518-2780-1, 70518-2780-0
Manufacturer
REMEDYREPACK INC.
Effective date
2022-02-02
Current FDA listing
Not matched in FDA.report NDC product tables

DailyMed Labels#

Label, Manufacturer, Effective date table
LabelManufacturerEffective dateType
Naloxone Hydrochloride - REMEDYREPACK INC.REMEDYREPACK INC.2022-02-02HUMAN PRESCRIPTION DRUG LABEL

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
70518-2780-02022-02-02C16284748780-1d6a99b39-47e2-a426-e053-dadaa90af4c24838e624-7b53-4e45-b42c-ef1213507188
70518-2780-02022-01-28C16284748780-1d6a99b39-47e2-a426-e053-dadaa90af4c24838e624-7b53-4e45-b42c-ef1213507188

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 6 of 6 · 103 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NALOXONE HYDROCHLORIDENALOXONE HYDROCHLORIDEBaxter Healthcare Corporation3d8813be-6d22-46f1-ac25-0d8a817a521c2020-11-25Warnings, Adverse reactionsExact identifier
unii: F850569PQR
Naloxone HydrochlorideNALOXONE HYDROCHLORIDEMylan Institutional LLCf0932877-1f3b-4d5e-82d2-dd6c53db47302020-08-17Warnings, Adverse reactionsExact identifier
unii: F850569PQR
Naloxone HydrochlorideNALXONE HYDROCHLORIDEHikma Pharmaceuticals USA Inc.8cc25cf1-008c-4808-baec-49f35a887fae2020-03-20Warnings, Adverse reactionsExact identifier
unii: F850569PQR

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.